Known targets — ChEMBL curated mechanism
ABL1BRAFDDR2EPHA2FGFR1FGFR2FLT1FLT4FRKKDRKITMAPK11NTRK1PDGFRAPDGFRBRAF1RETTEK
The experimentally established mechanism targets of Regorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.93 |
| ▸ | BRAF known ✓ | P15056 | 7/20 | 0.93 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.93 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.93 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 0.93 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.93 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.93 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.93 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.93 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.93 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 0.93 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.93 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.93 |
| ▸ | MAPK11 known ✓ | Q15759 | 2/20 | 0.93 |
| ▸ | DDR2 known ✓ | Q16832 | 2/20 | 0.93 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.78 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.78 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.78 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regorafenib SCHEMBL29351376 | 0.97 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29349808 | 0.97 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL432230 | 0.97 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29496390 | 0.96 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2554008 | 0.96 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2555101 | 0.96 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29555444 | 0.96 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2555800 | 0.93 | RAF1 (0.84) | RAF1BRAFKDRRETRIPK2 | |
| Sorafenib SCHEMBL1533972 | 0.92 | RAF1 (0.93) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL30433607 | 0.91 | RAF1 (0.89) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311220-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | BAYER HEALTHCARE LLC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170165243-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE, LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170165242-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | BAYER HEALTHCARE LLC (US) | 2017-06-15 | — | — | US | disclosed |
| EP-1793824-B1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUORO-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8680124-B2 | Treatment of cancers with acquired resistance to kit inhibitors | BAYER HEALTHCARE LLC (US) | 2014-03-25 | — | — | US | disclosed |
| US-8637553-B2 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | BAYER HEALTHCARE LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130183268-A1 | DRUG COMBINATIONS WITH FLUORO-SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | BAYER HEALTHCARE LLC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130131122-A1 | Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions | BAYER HEALTHCARE LLC (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2589384-A1 | New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders | Bayer Healthcare LLC (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2011130728-A1 | SYNTHETIC METABOLITES OF FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION DISEASES AND CONDITIONS | BAYER HEALTHCARE LLC (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20100267777-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1663978-B1 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | BAYER PHARMACEUTICALS CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1663978-A2 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060058358-A1 | Pharmaceutical compositions for the treatment of hyper-proliferative disorders | BAYER HEALTHCARE LLC | 2006-03-16 | — | — | US | disclosed |
| US-20050038080-A1 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005009961-A2 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165243-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | MKI67, CCNA1, CCND2 | RAF1 147/4885BRAF 102/4885KDR 2482/4885 |
| US-20130183268-A1 | DRUG COMBINATIONS WITH FLUORO-SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | DHFR, PCNA, FABP1 | RAF1 1817/4885BRAF 1020/4885KDR 3215/4885 |
| US-20060058358-A1 | Pharmaceutical compositions for the treatment of hyper-proliferative disorders | MKI67, CCNA1, CCND2 | RAF1 147/4885BRAF 102/4885KDR 2482/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | RAF1 59/4885BRAF 11/4885KDR 2076/4885 |
| US-20130131122-A1 | Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions | FLT1, FLT4, PDGFRA | RAF1 28/4885BRAF 16/4885KDR 8/4885 |
| US-20100267777-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | KIT, KRAS, CDKN1A | RAF1 91/4885BRAF 17/4885KDR 525/4885 |
| US-20180311220-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | KIT, NRAS, KRAS | RAF1 74/4885BRAF 20/4885KDR 427/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | RAF1 59/4885BRAF 11/4885KDR 2076/4885 |
| US-20050038080-A1 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | FLT4, FLT1, PDGFRB | RAF1 14/4885BRAF 7/4885KDR 5/4885 |
| US-20170165242-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | KIT, NRAS, KRAS | RAF1 74/4885BRAF 20/4885KDR 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.